24
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Assessing skin sensitization hazard in mice and men using non-animal test methods.

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Sensitization, the prerequisite event in the development of allergic contact dermatitis, is a key parameter in both hazard and risk assessments. The pathways involved have recently been formally described in the OECD adverse outcome pathway (AOP) for skin sensitization. One single non-animal test method will not be sufficient to fully address this AOP and in many cases the use of a battery of tests will be necessary. A number of methods are now fully developed and validated. In order to facilitate acceptance of these methods by both the regulatory and scientific communities, results of the single test methods (DPRA, KeratinoSens, LuSens, h-CLAT, (m)MUSST) as well for a the simple '2 out of 3' ITS for 213 substances have been compiled and qualitatively compared to both animal and human data. The dataset was also used to define different mechanistic domains by probable protein-binding mechanisms. In general, the non-animal test methods exhibited good predictivities when compared to local lymph node assay (LLNA) data and even better predictivities when compared to human data. The '2 out of 3' prediction model achieved accuracies of 90% or 79% when compared to human or LLNA data, respectively and thereby even slightly exceeded that of the LLNA.

          Related collections

          Author and article information

          Journal
          Regul. Toxicol. Pharmacol.
          Regulatory toxicology and pharmacology : RTP
          1096-0295
          0273-2300
          Mar 2015
          : 71
          : 2
          Affiliations
          [1 ] BASF SE, Experimental Toxicology and Ecology, Ludwigshafen, Germany.
          [2 ] BASF Personal Care and Nutrition GmbH, Düsseldorf, Germany.
          [3 ] BASF SE, Experimental Toxicology and Ecology, Ludwigshafen, Germany. Electronic address: robert.landsiedel@basf.com.
          [4 ] Procter & Gamble NV, 100 Temselaan, 1853 Strombeek-Bever, Belgium.
          [5 ] Procter & Gamble Technology (Beijing) Co., Ltd., China.
          [6 ] Procter & Gamble Company, Cincinnati, OH, USA.
          [7 ] Givaudan Schweiz AG, Ueberlandstraße 138, CH-8600 Dübendorf, Switzerland.
          [8 ] Shiseido Research Center, Shiseido Co., Ltd., 2-2-1 Hayabuchi, Tsuzuki-ku, Yokohama-shi, Kanagawa 224-8558, Japan.
          [9 ] Safety Science Research Laboratories, Kao Corporation, 2606 Akabane, Ichikai, Haga, Tochigi 321-349, Japan.
          Article
          S0273-2300(14)00309-2
          10.1016/j.yrtph.2014.12.008
          25541156
          1c2c94ba-0c4a-4f04-ada2-6ecbdbf354e5
          Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.
          History

          (modified) MUSST,Adverse outcome pathway (AOP),Allergic contact dermatitis (ACD),DPRA,Database,Integrated testing strategy (ITS),KeratinoSens™,LuSens,Skin sensitization,h-CLAT

          Comments

          Comment on this article

          Related Documents Log